Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells

Journal of Chemotherapy

Volumn 25, Issue 5, 2013, Pages 292-297

  Witort, Ewa ^a   Lulli, Matteo ^a   Carloni, Vinicio ^b   Capaccioli, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5 fluorouracil; Antisense oligonucleotides; Apoptosis; Chemoresistance; Hepatocellular carcinoma; Paclitaxel; Proteasome inhibitors; TRADD

Indexed keywords

ALLN PROTEASOME INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; FLUOROURACIL; PACLITAXEL; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MORTALITY; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; TIME-LAPSE VIDEO MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROTEASOME INHIBITORS; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN;

EID: 84884777155     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000087     Document Type: Article

References (26)

1. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-32.
2. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluoracil (ECF regimen). Cancer Chemother Pharmacol. 2002;50:305-8.
3. Micheau O, Tschopp J. Induction of TNF receptor 1-mediated apoptosis via two sequential signalling complexes. Cell. 2003;114:181-90.
4. Bender LM, Morgan MJ, Thomas LR, Liu ZG, Thorburn A. The adaptor protein TRADD activates distinct mechanisms of apoptosis from the nucleus and the cytoplasm. Cell Death Differ. 2005;12:473-8.
5. Zheng L, Bidere N, Staudt D, Cubre A, Orenstein J, Chan FK, et al. Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1. Mol Cell Biol. 2006;26:3505-13.
6. Jin Z, El-Deiry WS. Distinct Signalling pathways in TRAILversus tumor necrosis factor-induced apoptosis. Mol Cell Biol. 2006;26:8136-48.
7. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299-308.
8. Jones BE, Chau RL, Liu H, Srinivasan A, Streetz K, Valentino KL, et al. Hepatocytes sensitized to tumor necrosis factor-a cytotoxicity undergo apoptosis through caspase-dependent and caspase-independent pathways. J Biol Chem. 2000;276:705-12.
9. Sun BH, Zhao XP, Wang BJ, Yang DL, Hao LJ. FADD and TRADD expression and apoptosis in primary hepatocellular carcinoma. World J Gastroenterol. 2000;6:223-7.
10. Plumpe J, Malek NP, Bock CT, Rakemann T, Manns MP, Trautwein C. NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2000;278:G173-83.
11. Dai LC, Wang X, Yao X, Lu YL, Ping JL, He JF. Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells. Acta Pharmacol Sin. 2006;27:1630-6.
12. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol. 2002;3:112-21.
13. Inoue T, Shiraki K, Fuke H, Yamanaka Y, Miyashita K, Yamaguchi Y, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs. 2006;17:261-8.
14. Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs. 2008;17:879-95.
15. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004;23:2009-15.
16. Bernassola F, Ciechanover A, Melino G. The ubiquitin proteasome system and its involvement in cell death pathways. Cell Death Differ. 2010;17:1-3.
17. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ. 2010;17:14-24.
18. Morgan M, Thorburn J, Pandolfi PP, Thorburn A. Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol. 2002;157:975-84.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
20. Huang GC, Liu SY, Lin MH, Kuo YY, Liu YC. The synergistic cytotoxicity of cisplatin and Taxol in killing oral squamus cell carcinoma. Jpn J Clin Oncol. 2004;34:499-504.
21. Brenes O, Arce F, Gatjens-Boniche O, Diaz C. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluoracil on human hepatoma cell lines: possible mechanisms of cell resistance. Biomed Pharmacother. 2007;9:1-9.
22. Atencio IA, Ramachandra M, Shabram P, Demers GW. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ. 2000;11:247-53.
23. Ganten TM, Koschny R, Haas T, Sykora J, Weber ML, Herzer K, et al. Proteasome inhibition sesitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology. 2005;42:588-97.
24. Zhu H, Zhang L, Dong F, Guo W, Wu Z, Teraishi F, et al. Bik/ NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene. 2005;24:4993-9.
25. Lauricella M, Emanuele S, D'Anneo A, Calvaruso G, Vassallo B, Calisi D, et al. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis. 2006;11:607-25.
26. Fennel DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene. 2008;27:1189-97.